Alzheimer’s
Lilly’s drug for early Alzheimer’s shows promising results
August 6, 2025Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
July 3, 2024Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
FDA accepts Eisai’s Leqembi sBLA for early AD treatment
June 11, 2024Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …
Voyager Therapeutics shares data from preclinical programmes for Alzheimer’s treatment
February 21, 2024Research and Development Alzheimer's, Neurology, Voyager Therapeutics, preclinical
Voyager Therapeutics has announced new data from is two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease …
Eisai shares new data for Leqembi for Alzheimer’s treatment
October 26, 2023Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
Axol Bioscience and StrataStem collaborate to deliver ‘clinical trial in a dish’ for Alzheimer’s disease
June 7, 2023Research and Development Alzheimer's, Axol Bioscience, Neurology, StrataStem
Pluripotent stem cell technology provider Axol Bioscience has signed an exclusive agreement with UK-based StrataStem to access and commercialise its …
Eli Lilly to seek FDA approval for experimental Alzheimer’s drug
June 25, 2021Medical Communications Alzheimer's, Eli Lilly, FDA
Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …
Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate
March 10, 2021Research and Development Alzheimer's, Cassava Sciences, Evonik
Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …
Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial
January 11, 2021Sales and Marketing Alzheimer's, Eli Lilly
Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …
Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study
May 29, 2020Medical Communications Alzheimer's, leukaemia
The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …
Roche’s experimental Alzheimer’s drug does not meet primary endpoint in clinical trials
February 10, 2020Sales and Marketing Alzheimer's, Roche, roche Alzheimer
Roche has said its experimental drug, gantenerumab, did not meet its primary endpoint in people who have an inherited form …
Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal
January 14, 2020Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma
Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …
LSD treatment for Alzheimer’s patients proves safe in recent trial
December 19, 2019Business Services Alzheimer's, FDA, LSD, Magic mushrooms, psilocybin
The results of a Phase 1 clinical trial shows that Lysergic Acid Diethylamide (LSD) can be microdosed safely, and potentially …
China green lights first novel Alzheimer’s therapy since 2003
November 4, 2019Sales and Marketing Alzheimer's, China, Green Valley, Oligomannate, pharma
Shanghai Green Valley Pharmaceuticals has announced that its therapy Oligomannate (GV-971) has secured marketing approval from China’s National Medical Products Administration (NMPA) …
Axon seeks global partner after positive Phase 2 data for Alzheimer’s vaccine
September 10, 2019Manufacturing and Production, Sales and Marketing Alzheimer's, Alzheimers, Axon
Axon Neuroscience has announced data from its Phase 2 trial ADAMANT for the first-in-class vaccine AADvac1 to slow the progression …
